Mode
Text Size
Log in / Sign up
N/A Completed N=333 Randomized Other

The Smart Hypertension Control Study

Source: ClinicalTrials.gov NCT03288142 ↗
Enrolled (actual)
333
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcomePrimary: Blood Pressure at 6 Months — 135.0; 132.3; 85.6; 85.1 mmHG

Summary

Investigators at Northwestern University will partner with Omron Healthcare Co., Ltd. (hereinafter referred to as "Omron") to conduct a randomized controlled trial of a hypertension personal control program (HPCP), known as Lark HTN Pro with a home blood pressure monitoring device (HBMD) compared to a HBMD alone. The overarching goal of this study is to investigate the effects of the HPCP on blood pressure, blood pressure self-management behaviors, and healthy lifestyle behaviors among adults with hypertension.

Outcome Measures

OutcomeResultp-value
PRIMARY
Blood Pressure at 6 Months
135.0; 132.3; 85.6; 85.1
PRIMARY
Blood Pressure <140/90mmHg
72; 78
SECONDARY
Number of Antihypertensive Agents Used
1.3; 1.3
SECONDARY
Antihypertensive Medication Intensification, No. of Additions, Dose Increases, or Substitutions
0.3; 0.4
SECONDARY
Number of Health System Contacts (Telephone, Office, or Mychart Encounters)
7.0; 6.7
SECONDARY
Frequency of Home Blood Pressure Measurements Per Month
16; 17
SECONDARY
Months When a Home Blood Pressure Reading is Obtained, No.
4.9; 5.0
SECONDARY
Self-efficacy: Confidence in Controlling High Blood Pressure
4.4; 4.1; 4.8; 4.7; 4.0; 4.0
SECONDARY
BMI
32.0; 31.9
SECONDARY
Diet Quality Score (as Assessed by Dietary Approaches to Stop Hypertension Questionnaire, DASH-Q
38.7; 39.3; 1.3; 1.5; 1.0; 1.1
SECONDARY
Minutes Per Week of Self-reported Physical Activity
177.6; 143.1
SECONDARY
Self-reported Sleep Duration
6.6; 6.5

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18 years to <85 years at the time of screening
  • Standardized mean blood pressure measurement ≥135 to <180 mmHg systolic or ≥85 to <110 mmHg diastolic
  • Have and use an iOS device(s) (iPhone generation 5s or newer)
  • Able to provide written informed consent prior to participation in the study
  • Receive their primary care from a Northwestern Medicine clinic site

Exclusion Criteria

  • Current user of the HCPC (Lark HTN Pro)
  • Standardized mean blood pressure measurement ≥180 mmHg systolic or ≥110 mmHg diastolic
  • Persistent atrial fibrillation as indicated in the electronic health record (EHR)
  • Pregnant or planning to become pregnant during the study period
  • Severe kidney disease, defined as estimated glomerular filtration rate <30 per 1.73 m2 or currently on renal replacement therapy (i.e. hemodialysis or peritoneal dialysis)
  • Hearing impaired and unable to respond to phone calls
  • Lack of fluency in English
  • History of a cardiovascular event (stroke, transient ischemic attack, myocardial infarction, coronary artery bypass grafting) in the past 3 months
  • Diagnosis of dementia as indicated in the electronic health record
  • Diagnosis of psychosis as indicated in the electronic health record
  • Terminal cancer diagnosis or NYHA III or IV heart failure
  • Deemed unsuitable for study by primary care provider
  • Individuals requiring BP monitor cuff size larger than 17 inches or 42cm
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03288142). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search